Richard Barry is Director at Sarepta Therapeutics, Inc. (SRPT). They have made 20 open-market trades across 4 companies since 2012, most recently 2026-09-30.
CIK 0001562371
15 open-market purchases totalling $17.1M since 2016, against 5 sales. Across 13 scored buys the stock is up 0.5% at ninety days, and 4.3 points behind the S&P over the same stretch.
15 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SRPT | 2,983,542 | $51.0M |
| MDXG | 3,338,135 | $14.8M |
| SAVA | 938,060 | $2.2M |
| FLNA | 1,337,964 | $939K |
| TELK | 243,800 | — |
| Total | $69.0M |
Shares reported on the most recent Form 4, priced at the 2026-10-01 close. 1 holding could not be priced and is excluded from the total.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 38% | 38% |
| Avg Move | -3.2% | +0.3% | +0.5% |
| Alpha | -3.8% | -0.8% | -4.3% |
| Scored | 15 | 13 | 13 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FLNA | BUY | 2026-09-29 | 2026-10-01 | $0.91 | $278K | -24.3% | — | — |
| FLNA | BUY | 2026-09-28 | 2026-09-30 | $0.84 | $78K | -22.8% | — | — |
| SAVA | BUY | 2025-11-20 | 2025-11-24 | $2.76 | $828K | -1.2% | -31.0% | -33.1% |
| SAVA | BUY | 2025-11-19 | 2025-11-20 | $2.75 | $404K | +7.8% | -17.2% | -25.9% |
| SAVA | BUY | 2025-09-22 | 2025-09-23 | $2.28 | $16K | +9.7% | +18.1% | -28.1% |
| SAVA | BUY | 2025-09-18 | 2025-09-22 | $2.25 | $1.1M | +27.0% | +37.0% | -11.9% |
| SRPT | BUY | 2023-11-03 | 2023-11-06 | $78.81 | $3.9M | +2.9% | +8.4% | +55.7% |
| SAVA | BUY | 2023-08-21 | 2023-08-23 | $16.66 | $584K | +15.2% | -3.8% | +22.3% |
| SAVA | BUY | 2023-03-06 | 2023-03-08 | $25.81 | $4.6M | -4.0% | -15.2% | -14.5% |
| SAVA | BUY | 2022-08-23 | 2022-08-25 | $23.79 | $1.7M | -2.7% | +50.0% | +11.7% |
| SRPT | SELL | 2020-08-07 | 2020-08-07 | $158.50 | $9.5M | -6.1% | -18.5% | -8.3% |
| SRPT | SELL | 2020-05-15 | 2020-05-15 | $141.26 | $8.5M | +5.5% | +9.0% | +9.7% |
| SRPT | BUY | 2019-09-12 | 2019-09-16 | $87.49 | $875K | -16.7% | -0.8% | +54.8% |
| SRPT | BUY | 2019-08-20 | 2019-08-20 | $99.32 | $993K | -11.4% | -16.1% | -3.7% |
| SRPT | BUY | 2019-08-14 | 2019-08-14 | $122.50 | $453K | -24.7% | -30.5% | -19.2% |
| SRPT | BUY | 2019-08-12 | 2019-08-13 | $122.50 | $159K | -24.5% | -29.1% | -23.6% |
| SRPT | SELL | 2018-06-27 | 2018-06-29 | $130.34 | $9.8M | +4.2% | -12.6% | +20.7% |
| SRPT | BUY | 2016-03-14 | 2016-03-16 | $15.66 | $1.2M | +21.7% | +34.5% | +21.6% |
| TELK | SELL | 2012-12-17 | 2012-12-19 | $1.86 | $90K | N/A | N/A | N/A |
| TELK | SELL | 2012-12-12 | 2012-12-14 | $2.05 | $210K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.